B. Riley Equities Analysts Cut Earnings Estimates for CNTA

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Investment analysts at B. Riley decreased their Q1 2025 earnings per share estimates for Centessa Pharmaceuticals in a report issued on Thursday, March 27th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($2.01) EPS and FY2027 earnings at ($2.33) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04.

A number of other research firms have also recently issued reports on CNTA. Guggenheim restated a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $38.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $27.71.

Centessa Pharmaceuticals Stock Down 1.4 %

Shares of CNTA stock opened at $14.38 on Monday. The firm’s fifty day moving average price is $16.46 and its two-hundred day moving average price is $16.43. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.90 billion, a P/E ratio of -9.40 and a beta of 1.54.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $171,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the transaction, the insider now owns 54,322 shares of the company’s stock, valued at $1,033,747.66. The trade was a 35.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now directly owns 159,782 shares in the company, valued at approximately $2,631,609.54. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock worth $4,309,568 over the last three months. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.